Autres langues Alzamend Neuro, Inc.

Actions

ALZN

US02262M4078

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
0,711 ^USD	+0,14 %		-2,01 %	-20,11 %

25/03	Alzamend Neuro, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 31 janvier 2024	CI
05/01	Alzamend Neuro, Inc. nomme Milton C. Ault, III en tant qu'administrateur et vice-président	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	25/03
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	31/01
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	05/01
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	15/12
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12/12
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	11/12
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	20/11
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	20/11
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	20/11
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	17/11
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	16/11
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	13/11
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	13/11
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/10/23
Alzamend Neuro Announces Reverse Stock Split	30/10/23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001	24/10/23
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23/10/23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	23/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alzamend Neuro, Inc.

Actions

ALZN

US02262M4078

Autres langues

Filtres